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Abstract
To our knowledge, there is no report on long-term reproductive and developmental side effects in the offspring of
mothers treated with a widely used chemotherapeutic drug such as doxorubicin (DXR), and neither is there information
on transmission of any detrimental effects to several filial generations. Therefore, the purpose of the present paper was to
examine the long-term effects of a single intraperitoneal injection of DXR on the reproductive and behavioral
performance of adult female mice and their progeny. C57BL/6 female mice (generation zero; G0) were treated with either
a single intraperitoneal injection of DXR (G0-DXR) or saline (G0-CON). Data were collected on multiple reproductive
parameters and behavioral analysis for anxiety, despair and depression. In addition, the reproductive capacity and health
of the subsequent six generations were evaluated. G0-DXR females developed despair-like behaviors; delivery
complications; decreased primordial follicle pool; and early lost of reproductive capacity. Surprisingly, the DXR-induced
effects in oocytes were transmitted transgenerationally; the most striking effects being observed in G4 and G6,
constituting: increased rates of neonatal death; physical malformations; chromosomal abnormalities (particularly deletions
on chromosome 10); and death of mothers due to delivery complications. None of these effects were seen in control
females of the same generations. Long-term effects of DXR in female mice and their offspring can be attributed to genetic
alterations or cell-killing events in oocytes or, presumably, to toxicosis in non-ovarian tissues. Results from the rodent
model emphasize the need for retrospective and long-term prospective studies of survivors of cancer treatment and their
offspring.
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Introduction
Chemicals used in the treatment of cancer are unquestionably
beneficial as therapeutic agents. Nevertheless, the ensuing
detrimental reproductive and developmental problems for both
the treated mothers and their offspring cannot be ignored
[1,2,3,4,5,6,7,8,9,10,11,12,13]. In the USA it is estimated that
by the end of 2010, 1-in-60 women under the age of 39 will be a
cancer survivor who has been exposed to a chemotherapeutic
agent [14,15]. How many of those survivors of cancer treatment
will become pregnant remains unknown; however, it is grossly
estimated that at least half of them will do so [16,17,18].
Unfortunately, there is a paucity of information on the effects of
chemotherapeutic agents on the offspring of cancer survivors that
received chemotherapy.
Therefore, the present experiments were designed to
examine the long-term effects of a single intraperitoneal
injection of DXR on the reproductive and behavioral
performance of adult female mice and their progeny. We
observed that when young adult females are treated with
doxorubicin (DXR), a widely used chemotherapeutic agent
[19], the animals develop dysfunctions in multiple organs,
including the brain, uterus, and ovaries. Surprisingly, the
doxorubicin-induced effects in oocytes were transmitted
transgenerationally by both males and females born to a
chemo-treated mother. To our knowledge, this is the first
report on transmission of chemotherapy effects to several filial
generations. The mechanisms for transgenerational transmis-
sion of the chemotherapy-related phenotypes remain to be
determined. However, the observed chromosomal abnormali-
ties and the increase in severity of symptoms in generations four
and five, let us to hypothesize that DXR-induced damage in
female gametes is characterized by chromosomal deletions that
genetically compound over two generations [20,21,22,23].
This manuscript highlights the importance and the need for
long-term follow-up of survivors of cancer treatment and their
offspring. Our data suggest that most of the childhood cancer
survivors (approximately one in 900 adults in the United States)
[24] –together with their offspring – might be at risk for late
e f f e c t sf r o mc h e m o t h e r a p y .R e s u l t sf r o mt h ep r e s e n te x p e r i -
ments may provide valuable prognostic information for this
growing human population; such data are pertinent considering
that reproduction remains an option for adults in this
population.
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DXR treatment resulted in permanent depletion of
primordial follicles
Recently, it has been suggested that DXR-induced depletion of
the primordial follicle pool is a temporary state, and that 48 h after
a single intraperitoneal injection of DXR (5 mg/kg), replenish-
ment of the primordial follicle pool somehow resumes and reaches
control values by the second month after treatment [25]. In an
effort to replicate such findings, we performed a series of
experiments under the exact same conditions as Johnson et al.
Our results confirmed those previously reported by us
[26,27,28,29] and others [29,30,31,32] in that DXR causes
depletion of the primordial follicle pool in a time dependent
manner (Fig. 1A&B). On the other hand, DXR does not appear to
affect follicles beyond those in the primary stage (Fig. 1C&D). The
disappearance of primordial follicles was evident 36 h after a
single intraperitoneal injection of DXR, and by two months their
number was almost close to zero. Four and six months after the
treatment, the primordial follicle pool remained almost totally
depleted with less than 20 primordial follicles remaining in the
ovaries (Fig. 1B, &E–H). Therefore, unlike Johnson et al., we did
not observe replenishment of the primordial follicle pool; the
reason for the discrepancy between our study and that of Johnson
et al. [25] remains to be determined.
DXR induced myometrial damage and death of treated
mothers due to delivery complications
Contrary to the induction of damage and depletion of the
primordial follicle pool, DXR does not appear to affect the pools of
follicles already in the growing phase (Fig. 1C&D). Henceforth, we
sought to determine what effects DXR has on the fertility of treated
females. At seven weeks of age, female mice were given a single
intraperitoneal dose of DXR (10 mg/Kg; N=50). Two months
after treatment, females were individually caged with young (8
weeks of age) adult males of proven fertility. As expected for a drug
that does not affect the antral follicles and ovulation (Fig. 1C&D),
there was no significant difference in pregnancy rates between
control and the chemotherapy group. From 30 control females
(receiving a single intraperitoineal injection of saline), 29 got
pregnant and delivered within 30 days of being caged with males.
These females all delivered normally, and the number of pups/litter
was also normal (average 862 pups/litter). In the chemotherapy
group (N=50), 47 females got pregnant within 30 days of being
caged with males. Unexpectedly, 66% of the DXR-treated females
had dystocia and died during delivery. The remaining females
(34%) delivered normally, although they had less pups/litter
(average 461 pups/litter; p,0.05 compared to CON), which
reflects the diminished primordial follicle pool in these females.
Although, how DXR affects uterus function is unknown,
previous studies found adverse side effects of DXR on various
tissues (e.g. heart, brain, eyes, liver) [33,34,35,36,37]. Specifically,
DXR decreases muscle mass and tone in some tissues [38,39].
Therefore, we hypothesized that the delivery complications
observed in DXR-treated females must have been the result of
DXR actions on the uterus. We observed apparent macroscopic
differences between control (Fig. 2A&B) and treated (Fig. 2C&D)
females; uteri from treated females were smaller. Histological
analysis of those uteri revealed that the thickness of the myometrial
layers of DXR-treated females was highly decreased
(5.760.25 mm, N=30, Fig. 2G&H) compared to untreated
females (1061.3 mm, N=30, Fig. 2E&F). In addition, in treated
females, sarcopenia (decreased muscle fibers) of the outer
myometrial layers was apparent (Fig. 2H), these side effects were
observed in approximately 70% of treated females.
This finding could explain the delivery complications we
observed. We conclude that the uterine anatomic changes
contribute to the delivery complications observed in DXR-treated
females. We postulate that the compromised uterine muscles in
DXR-treated females could not generate enough force to complete
delivery. Oxytocin injections (2 injections 30 min apart at the time
of delivery) were not effective, in few DXR-treated females (2 out
of 15 females) it only helped to deliver one pup, while the rest of
the litter remained retained. The mothers died due to complica-
tions following dystocia, fetal maceration and bacterial infection.
When C-section was performed at the first signs of parturition, the
procedure was an efficient intervention to rescue the pups (N=42
pups from 10 treated females) as opposed to oxytocin treatment.
DXR affected both the oocyte and the uterine
environment
We noticed that surviving pups born to a chemotherapy-treated
mother were physically weaker compared to control. Therefore, to
determine the role played by the oocyte and the uterine
environment in the DXR-induced delivery complications and poor
health of the neonates, we performed ovary transplants involving
swaps between DXR-treated and control females (Fig. 3). Females
were treated with a single intraperitoneal dose of either sterile saline
(CON;N=37) orDXR(N=37) whentheywere7weeksofage.Six
weeks post-treatment, the ovaries were surgically removed from
both CON and DXR-treated females. The control ovaries were
then transplanted into DXR-treated females (CONov-DXRuterus),
whereas the DXR-treated ovaries were transplanted into CON
females (DXRov-CONuterus). Two weeks after surgery, females
were mated with young males of proven fertility. Five ovariecto-
mized (OVX) control females that didn’t receive ovaries were also
caged withmales, and as expected, no pregnancies were observed in
any of them. Approximately 70% (26 out of 37) of control females
receiving DXR ovaries (DXRov-CONut) got pregnant. However,
22% (6 out of 26) of those females had delivery complications and
died; no histological alterations were observed in the myometrium
of these females (data not shown). The rest of those females
delivered normally, although the litters were smaller and the pups
weaker; among those pups, the rate of neonatal death was 83%
(from 36 pups born, 30 died during the first week). In the CONov-
DXRut group, the pregnancy rates decreased to 35% (13 out of 37),
and seventy percent of those pregnant females (9 out of 13) died at
the time of delivery due to dystocia-associated complications. The
remaining 30% (4 females) delivered a total of 8 pups, though
smaller in size but otherwise normal.
These results suggest that pregnancy and delivery complications
seen in DXR-treated females or females that got DXR-treated
ovaries appear to be mostly linked to uterine health (78%
contribution); however there was also a 22% contribution by the
oocyte. Importantly, the health of the neonates appears to be
primarily controlled by the oocyte (83% contribution). But, in
those transplant experiments, the contribution of the immune
system due to immunological rejection cannot be totally ruled out,
even though the mice were syngeneic.
DXR-induced effects on the oocyte were transmitted
transgenerationally
In an effort to elucidate the role that DXR-exposed oocytes play
in the delivery complications, we monitored the offspring of the
treated and control G0 females for six generations. Firstly, we
tested if oocytes recovered from the G0-DXR females were more
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PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17877Figure 1. Assessment of ovarian reserve after in vivo exposure to DXR. (A,B) DXR caused depletion of the primordial follicle pool in a time
dependent manner.
** P,0.001 relative to CON; opened bars (vehicle CON); filled bars (DXR); the number of mice analyzed per group is provided in
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females were markedly decreased (762.2 oocytes/female com-
pared to 1561.87 oocytes/female in the control; p,0.05; Fig. 4),
those oocytes were equally sensitive to DXR as the control. By the
time the G0-DXR females were 8 months of age no oocytes could
be recovered after superovulation; we were unable to harvest
immature oocytes from the ovary as well. In any case, no G0-
DXR female delivered after 6 months of age, whereas control
females kept delivering until approximately 10–12 months of age.
Pups that survived after the first week (from now on called G1)
developed normally. Compared to CON, in G1-derived oocytes
there were no significant differences in their ovulation rates or in
the in vitro sensitivity of oocytes to DXR. Fertility rates of G1 males
and G1 females were also not different from control (G1 N=20
males and 20 females, and they produced approximately 130 pups
here called G2). However, when semen analyses were performed,
a marked decrease in sperm concentration was observed at the first
generation (G1) and remained low for the subsequent six
Figure 2. DXR induced atrophy of the myometrium. (A–D) Macroscopic appearance of uteri from two different females at two months after
treatment with either saline (A,B) or DXR (C,D). Notice the difference in the thickness of the uterine horns. (E–H) Uterine sections stained with H&E.
Notice the decrease in the thickness and sarcopenia of the outer myometrial layers of DXR-treated females (G,H) compared to control females (E,F).
doi:10.1371/journal.pone.0017877.g002
parentheses above each bar. (C,D) DXR did not affect follicles beyond those in the primary stage; as depicted in these micrographs, several antral
follicles (black stars) and corpora lutea (white stars) are present in the ovaries of treated females. (E,F) Some primordial and small follicles were still
present in the ovaries of CON females six months after treatment. (G,H) The ovaries of DXR-treated females at 6 months of age resembled the ovaries
of very old females, with no follicular structures or corpus luteum present; moreover those ovaries had shrunk to approximately half size compared to
CON ovaries from females of the same age, compare E and G.
doi:10.1371/journal.pone.0017877.g001
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generations do not show significant changes in the sperm
concentrations compared to the Go. In both sexes, there was a
marked decrease in fertility in G2. In females, the most striking
transgenerational effects were observed in G4 and G6, where we
found increased rates of neonatal death and physical malforma-
tions, predominantly head abnormalities (Fig. 6A&B), chromo-
somal abnormalities, particularly deletions on chromosome 10 in
all abnormal pups genotyped (N=7; Fig. 6C), and death of
mothers due to delivery complications (Table 1). The affected
females exhibited thinner myometria (Fig. 6F&G) compared to
females that delivered normally (Fig. 6D&E). Note that none of
these effects were seen in the control females of the same
generations.
Positive correlation between deletions in chromosome
10 and the presence of ring-like cells
Following observation of high rates of neonatal death in G4 and
G6 (Fig. 7A), and malformations in G4 (Table 1), we decided to
karyotype those pups. Interestingly, the specimens from the pups
exhibited a deletion in chromosome 10. Furthermore, during the
karyotyping analysis, it was discovered that the cultures being
karyotyped possessed rare cells called ‘ring- and/or hyposegmen-
ted-cells’. Intriguingly, we also found significant numbers of ring-
like cells (Fig. 7D) in the peripheral blood of G3, and G5 parents
(both males and females) that gave rise to either abnormal pups
and/or pups that died during the first week of life (Fig. 7B&C).
Moreover, we found a remarkably tight correlation (r=0.91)
between the presence of those cells in peripheral blood and the
increase of abnormal pups and/or dead neonates in the following
generation (Fig. 7A). Interestingly, a percentage of ring-like cells
$2% in either parent directly correlates with problems seen in the
generation immediately after.
Short-term starvation (STS) decreased the duration of the
initial distress caused by chemotherapy
Since DXR is a highly used and effective chemotherapeutic
agent, it is important to identify approaches to either totally
Figure 3. Schematic representation of the ovarian transplantation and mating trials. Control ovaries were transplanted into DXR-treated
females, and DXR-treated ovaries were transplanted into CON females. Two weeks after surgery, all recipients were placed in mating trials with adult
males of proven fertility.
doi:10.1371/journal.pone.0017877.g003
Figure 4. Ovulation rates of G0 females at two and six months
after treatment. The ovulation rates of G0 females treated with DXR
were markedly decreased compared to CON.
* P,0.05; opened bars
(vehicle CON); filled bars (DXR); the number of mice analyzed per group
is provided in parentheses above each bar.
doi:10.1371/journal.pone.0017877.g004
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proposed that fasting before chemotherapy could decrease the side
effects in people undergoing chemotherapy [40,41]. Herein, we
found that in female mice, fasting for 48 h before a single dose of
DXR decreases the early observable side effects of the drug, i.e.,
freezing behavior, ruffled hair, and hunched back posture. While
DXR-treated females displayed those distressed signs for approx-
imately 21 min (AVG 1963 min; N=30; DXR), in females
undergoing STS before treatment this time span was shortened
considerably (AVG 1263 min; N=30; STS+DXR), although still
higher than control animals (immobility time average
0.460.2 min; N=15). Fasting for 48 h also partially protected
the myometrium (7.160.25 mm, N=20; compared to DXR alone
5.760.25 mm, N=30; p,0.05), but it didn’t prevent delivery
complications and death of mothers and pups. Apparently, losing
25% or more of the myometrial thickness could have devastating
consequences. Fasting for 48 h appeared to partially protect the
primordial follicle pool, although the difference was not significant
(data not shown).
In humans the recommended fasting period is 72 h [41], so it
remains to be determined if in mice increasing the fasting period
by 24 h would have more dramatic benefits beyond those
observed post 48 h STS. Since most complaints from chemother-
apy patients refer to the immediate side effects of the drugs [36],
we speculate, based on our results, that STS might indeed be
useful in reducing such undesirable outcomes.
DXR induced anxiety and despair-like behaviors that
were corrected either by pre-treatment with S1P or
deficiency of Bax
To continue our studies on the side effects of chemotherapy and
how to either prevent or control them, we analyzed behavioral
changes. We performed neurobehavioral phenotyping of the
following groups of females: CON (N=20); DXR (single dose,
N=25); and S1P+DXR (N=30). Since, in earlier studies [27,28],
we reported that bax-KO mice are protected from many of the
undesirable effects of DXR, in these experiments we included a
fourth group consisting of bax knockout females (bax-KO, without
and with DXR; N=10 and N=15, respectively).
We examined depression/despair-like behaviors by tail suspen-
sion test and forced swimming test [42]. In the ‘Tail Suspension
Test’ [42] the animal is suspended by its tail from the ceiling of the
chamber, the duration of immobility is then recorded and inferred
as an index of behavioral despair. In this test, we found no
significant differences between the groups.
The ‘Forced Swimming Test’ chronicles behavioral changes
where mice are forced to swim in un-escapable situation. The
immobility observed in this test is considered to reflect a state of
despair. CON, S1P+DXR, and bax-KO+DXR females floated less
(i.e. less immobility) compared to the DXR group (Fig. 8A–C),
possibly indicating lower levels of despair.
As patients undergoing chemotherapy frequently complain
about changes in behavior, particularly anxiety [34,36], we
evaluated anxiety levels in our mice using ‘Elevated Plus Maze’.
In this test, when mice are initially introduced into a maze, they
perform risk assessments before deciding to move onto any arm of
the maze. More anxious mice spend more time assessing the risk
(i.e. higher number of risks assessments) of moving out of the
familiar environment (closed arms). Although we found no
significant indication of anxiety in the DXR-treated females, it is
worth mentioning that the S1P+DXR group differed significantly,
since the females executed less risk assessments compared to the
other two groups (Fig. 8D). This could be an indication of their
lower level of anxiety. Therefore, it would be interesting to
evaluate further the therapeutic potential of S1P as an anxiolytic
drug. Unlike humans, female mice treated with chemotherapy
seem to be more prone to despair and not anxiety.
Discussion
The present report examines the effects of a single intraperi-
toneal injection of DXR on the reproductive and behavioral
performance of adult female mice and their progeny. In earlier
studies [13,16], it was suggested that oocytes that survive DXR
treatment might be less capable of being fertilized successfully.
Our results demonstrate that this is not the case, as there was no
difference in pregnancy rates between G0 treated and CON
females. However, our studies unveiled important reproductive
risks for both the treated mother and her G4 and G6 descendants
(see below). The delivery complications we observed in G0
females treated with DXR have not been reported in humans.
Nonetheless, it is important to note that human pregnancies
following chemotherapy are considered high risk in nature and
delivered via C-section [3,8,10,11,12,43]; and as we reported here
C-section was a very effective intervention to rescue pups and
prevent delivery complications. An issue that we did not
address in the present studies is whether or not G0 females that
delivered normally would have had any problems in subsequent
pregnancies.
In any case, no G0 female delivered after 6 months of age. This
was expected since in these females the primordial follicle pool has
Figure 5. Sperm analysis for control males and males born to
DXR-treated mothers over six generations. (A) A marked decrease
in sperm concentration was observed at the first generation (G1) and
remained below CON levels for the subsequent five generations
studied. (B) Motility on the other hand appeared to improve over
several generations. Control males of the same generations do not
show significant changes in either the sperm concentrations or sperm
motility compared to the Go. *P,0.05; **P,0.001; ***P,0.0001;
opened bars (CON); filled bars (offspring of DXR-treated females); the
number of mice analyzed per group is provided in parentheses above
each bar.
doi:10.1371/journal.pone.0017877.g005
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reproductive capacity was about 4 months earlier in the treated
G0 females than in control females. In women, this would be the
equivalent of onset of menopause, and agrees with current
knowledge on the induction of early menopause (occurring 8
years earlier) in women following chemotherapy treatment
[2,6,7,9].
That DXR is a female germ cell mutagen has been previously
demonstrated [20,44,45,46]. Those earlier studies [20,44,45] and
the present one raise the possibility of transmissible genetic damage
induced in germ cells. However, the chromosomal abnormalities
observed in those studies and the ones reported here are different.
This could be due to differences in either dose, strain of mice, and/
or length of treatment. There are also earlier publications on the
effects of chronically administered chemotherapeutic agents (e.g.,
cyclophosphamide) on the immediate offspring of mice and rats
[47].But,toourknowledge,thereisnoreportonthetransmissionof
any chemotherapy effects to several filial generations, and that’s
what makes the present manuscript unique. Therefore, retrospec-
tive and long-term prospective studies of the subset of human
population are needed to ascertain the issues discussed. Our main
motivation is to raise awareness about the importance and the need
for long-term follow-up of survivors of cancer treatment and their
offspring. Such data would be beneficial for genetic counseling of
childhood cancer survivors; this subpopulation of approximately
one in 900 adults in the United States [24] –together with their
offspring– might be potentially at risk for the transgenerational
effects from chemotherapy.
Although, with the present experiments we can not exclude the
possibility as to whether the effects we saw were due to either
DXR or any of its metabolites [19,48]; it is clear that, a single dose
of DXR was able to cause the observed plethora of undesirable
effects in both the mother and her G4 and G6 descendants as well.
As of date, 40 years after its first usage [49], transgenerational
effects of DXR in the human population have not been reported.
This might be due to the fact that the most devastating
consequences we observed (i.e. increases in neonatal death rates
and malformations), are expected to manifest at the earliest in G4.
This means approximately 70 years after dosing the G0 parent,
based on a hypothetical example of a girl (G0) getting treatment at
the age of 10 years, delivering the G1 at the age of 21.4 (according
to the CDC data from 1970; [50]), and assuming that the average
age of first time moms for the subsequent generations increases at
an average of 0.11 yearly.
As to how DXR induces all those effects, our data point to both
genetic (chromosomal deletions) and non-genetic mechanisms as
possibly underlying the different effects seen in the present studies.
It has been proposed that DXR exerts antitumor activity by
interacting with DNA and interfering with its metabolism [19].
However, some of the toxicity of this drug has also been related to
interfering with mitochondrial functions [51,52]. In general,
enzyme inhibitions [19], lipid peroxidations [53], membrane
disorders and oxidative stress [34,51], are now being associated
with the toxic side effects of DXR. Although at this time we cannot
pinpoint the exact mechanism(s) involved in the transgenerational
effects, several facts from our results led us to speculate that they
can be partly attributed to dysfunction of mitochondria and
inheritance of those dysfunctional organelles. Our first conviction
is based on observation of acceleration of aging-like phenotypes in
ovary, uterus, and brain; each one of those tissues exhibited
degenerative changes previously attributed to mitochondrial
dysfunction [34,54,55]. Secondly, there is the fact that, the
phenotype skips generations, which reflects a landmark of
mitochondrial inheritance [56,57,58,59,60]. And thirdly, more
individuals in a litter are affected when the mother (and not the
father) is the suspected carrier. Note that practically all
mitochondria in an individual are provided by the oocyte
[58,61,62]. Furthermore, considering the fact that mitochondria
are crucial for maintaining oocyte health and developmental
potential [34,54,62], and since oocytes are the cells in the body
with the higher number of mitochondria [58,62], one can envision
why these organelles could be the most likely targets of DXR-
induced damages in oocytes of the G0 female.
The observed chromosomal abnormalities and the increase in
severity of symptoms in generations four and six, led us to
hypothesize that DXR-induced damage in female gametes is
characterized by chromosomal deletions that genetically compound
over two generations [20,44,45]. DXR shows a wide range of effects
on mammalian oocytes [7,20,23,26,44,45], therefore, additional
analysis is needed for a global view of oocyte response to this agent
at the genome level [63]. Recent efforts in our laboratory are
oriented towards oocyte genomic profiling and identification of the
genespresentinthedeleted regionofchromosome10.Such analysis
would yield insight into the molecular mechanisms of DXR injury
in oocytes and other tissues as well, and would help in the rationale
of designing more effective treatment strategies to circumvent the
unwanted side effects of this drug.
Based on the percentages of ring-like cells in peripheral blood of
offspring of the G0 treated female, we were able to predict male and
female carriers (possess higher risk of producing abnormal litters)
with an accuracy of 90% or higher. However, the exact relationship
between the ring-like cells and the chromosomal aberrations
observed is not yet clear in terms of etiology. Nonetheless, this
Table 1. Reproductive outcomes by generation.
Generation CON G0 G1 G2 G3 G4 G5 G6
Number of females 50 50 30 30 30 37 30 30
AVG age at first pregnancy
after treatment (mo)
4 4 2.5 2.5 2.5 2.5 2.5 2.5
AVG number of pregnancies
over 8 mo breeding
7 16344 7 7
AVG number of live pups
over 8 mo breeding
9 38553 8 6
Percentage of spontaneous
early pregnancy losses
0 00330 0 0
Percentage of females dying
at delivery
0 5 6 0069 0 0
Percentage of abnormal pups 0 00017 0 0
doi:10.1371/journal.pone.0017877.t001
Figure 6. Representative images of transgenerational phenotypes observed in offspring of DXR-treated (G0) females. (A) Examples
of normal pups (day 0) born to CON females. (B) Physical malformations, particularly head abnormalities were observed in G4 pups (day 0), but note
that only the G0 female was treated with DXR. (C) Representative karyotype of abnormal G4 pups, depicting a large deletion on chromosome 10.
(D–G) Histological appearance of uteri from control (D,E) and G4 (F,G) females. Notice the thinner myometria in G4 females although they were never
treated with DXR; only the G0 females received DXR. Compare the marked layers in E&G. Note that none of these effects were seen in the control
females of the same generations.
doi:10.1371/journal.pone.0017877.g006
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our future genetic studies, and may also provide a potential
biomarker for a diagnostic/screening tool in human clinics.
Neutrophils with ring-shaped nuclei have been described in
human patients with myeloproliferative hematologic diseases [64,65].
In our studies the mice possessing the ring-like cells look normal, and
except for females that died due to delivery complications, we did not
observe any other complications. Hence, most probably we can
exclude the presence of a myeloproliferative disease. However, we
cannot totally rule out the possibility that the mice could develop the
disease later in life, most probably beyond 15 months of age;
unfortunatelyin these studies we never kept our micebeyond this age.
Thus, we have shown that a reduction in the fertility of female
mice and their offspring after DXR treatment can occur and can be
attributed to genetic alterations or cell-killing events in oocytes or,
presumably, toxicosis in non-ovarian tissues. DXR effects are not
germ cell specific, and therefore the potential for failure of multiple
biochemical pathways and deregulation of gene expression should
be considered when trying to understand cell damage due to DXR.
Materials and Methods
Animals
For all experiments C57BL/6 mice were purchased from
Charles River Laboratories at 6 weeks of age. Mice were kept in
well-controlled animal housing facilities. Experiments were
performed when the females were 7-week old. Their access to
water and food was unrestricted, except in the experiments under
short time starvation when food was removed for 48 hours. In the
first set of experiments in which we replicated the studies by
Johnson et al. [25], DXR was given as a single intraperitoneal dose
of 5 mg/Kg. In all the other experiments, females G0 were treated
with either a single intraperitoneal injection of DXR (10 mg/Kg)
[26]; or saline, or two doses of S1P (Biomol, Plymouth Meeting,
PA, USA; 20 mg/dose diluted in 50 ml) [66,67]; via retroorbital
injections at 18 h and at 30 min prior to the DXR treatment. All
experiments involving animals described herein were reviewed
and approved by the institutional animal care and use committee
(IACUC) of Michigan State University (IACUC 12-07-178-00).
Histomorphometric analysis of follicle numbers
Ovaries were collected at 12 h, 36 h, 48 h, 120 h, and at 2, 4
and 6 months after DXR treatment. Control ovaries were
collected from vehicle-treated animals. Tissues were fixed (0.34
N glacial acetic acid, 10% formalin and 28% ethanol), embedded
in paraffin and serially sectioned (thickness, 8 mm). The serial
sections from each ovary were stained with hematoxylin and picric
acid methyl blue, and every tenth section was analyzed for the
number of healthy (non-atretic) primordial, primary and small
preantral follicles, as described [26,28,68,69]. For animals six
months and older, every single section was subjected to counting
(to avoid missing any primordial follicle).
Histomorphometric analysis of myometrial thickness
Uteri were collected at 12 h, 36 h, 48 h, 120 h, and at 2, 4 and
6 months after both DXR treatment and control. Tissues were
fixed, embedded in paraffin and sectioned (thickness, 8 mm). For
each female, two or three full cross- and longitudinal-sections of
uteri were stained with hematoxylin and eosin, photographed, and
myometrial thickness measured in the largest full cross-section.
Ovarian transplantation and mating trials
As described [70], six weeks after the DXR treatment, one
control and one DXR-treated female were anesthetized, and
prepared for aseptic surgery. Both ovaries of each female were
Figure 7. Neonatal death rate and percent of ring-like cells in peripheral blood of CON, G0 and their offspring over six generations.
(A) Note the increased rates of neonatal deaths in G0, G4 and G6. (B,C) Significant numbers of ring cells were found in the peripheral blood of G3,
and G5 parents (both males and females) that gave rise to either high rates of neonatal death and/or abnormal pups. (D) A positive correlation
(r=0.91) between the presence of ring-like cells in peripheral blood and the appearance of the abnormal pups in the following generation.
doi:10.1371/journal.pone.0017877.g007
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area, and placed in separate (CON or DXR) Petri dishes containing
2 ml of modified human tubal fluid (Irvine Scientific, Santa Ana,
CA). Next, CON ovaries (left and right) were transplanted into the
corresponding empty ovarian bursas of the DXR-treated female.
The incision was closed with surgical clips.The same procedure was
thenrepeatedfortransplantingtheDXRovariesintoCONfemales.
Two weeks after surgery, all recipients were placed in mating trials
with adult males of proven fertility. The mating trials continued
until the females were 15 months of age, or until death, which
usually occurred prior to 15 months in the treated animals.
Oocyte Collection and Culture
Female mice were superovulated with a hormonal regimen of
eCG/hCG as previously described [26,54,71]. Mature oocytes
were collected from the oviducts 16 h after hCG injection and
cultured in vitro as previously described [26,54,71]. Assignment to
treatment groups was carried out at random, and incubations for
up to 24 h performed without or with freshly made DXR
(200 nM; Alexis Biochemicals, San Diego, CA).
Analysis of Apoptosis
At the end of the culture period, the oocytes were fixed and
evaluated as detailed previously [27,72,73], for characteristics of
apoptosis, including morphological changes (e.g., condensation,
budding and cellular fragmentation) and biochemical alterations (i.e.,
DNA cleavage; Comet Assay Kit, Trevigen, Gaithersburg, MD). The
percentage of oocytes that underwent apoptosis out of the total number
of oocytes cultured per drop in each experiment was then calculated.
Semen analysis
Sperm were collected from cauda epididymis and capacitated in
vitro for 1 h. Immediately after, sperm motility (path velocity,
progressive velocity and track speed) and concentration were
evaluated by computer-assisted sperm analysis (CASA) using
Hamilton-Thorne IVOS 12.3 as previously described [74].
Behavioral phenotyping
Behavioral analyses for anxiety (elevated plus maze), despair
and depression (tail suspension and forced swimming tests) were
performed at the Toronto Center for Phenogenomics (www.cmhd.
ca) using standard approved procedures [75].
Karyotyping
C-banded karyotypes of somatic chromosomes from live
cultures and tissues were performed by Cell Line Genetics
(Madison, WI), using standard protocols [76].
Blood smears
A small drop of blood was collected from the tail; blood smears
were prepared, allowed to dry, fixed with methanol, and stained
Figure 8. Behavioral phenotyping of G0 females. (A–C) The immobility observed in this test is considered to reflect a state of despair. CON,
S1P+DXR, and bax-KO+DXR females floated less (i.e. remain less time immobile) compared to the DXR group, possibly indicating lower levels of
despair in those females. While A&B illustrate the average time females remained floating, C depicts the percentage of females in the treated groups
that remained floating longer than the control. (C) 40% of the females in the DXR group were above the maximum immobility time of the CON (i.e.
more females in this group remain immobile and for longer periods); in the S1P+DXR group, only 16% of the females were over the maximum times
in the control average. (D) Mice that perform more assessments and spend more time assessing the risk of moving out of the familiar environment
are considered more anxious. Only the S1P+DXR group executed fewer risk assessments compared to the other two groups, indicating low level of
anxiety. *P,0.05; **P,0.001; the number of mice analyzed per group is provided in parentheses above each bar.
doi:10.1371/journal.pone.0017877.g008
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pathologist having no knowledge of the experimental groups.
Data presentation and statistical analysis
All experiments were independently repeated for at least three
times (unless stated otherwise) with different sets of mice. Data not
differing significantly were pooled by groups. The combined data
from the replicate experiments were subjected to a one-way
analysis of variance followed by Scheffe’s F-test, Fisher’s exact test
or Student’s t-test. Differences between group means were
considered statistically significant at P,0.05. The data depicted
in graphs represent the mean 6 SEM of the combined data.
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